gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LABHealthcarePharmaceuticals

Standard BioTools Inc. Common Stock (LAB)

$0.6160+0.85%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.62▼ 48.24% in range
Nov 4, 2025Low $0.60 · High $1.68Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Standard BioTools closed at $0.62 on Nov 4, up 0.85%, within 2.7% of its 52-week closing low. Volume of 1.0M shares was 1.16× its 20-day average (close to normal).

Split-adjusted performance: -14.7% over one month, -36.4% over six months, -50.3% over one year.

In the quarter ended Sep 30, 2026, revenue was $19.39M, down 0.9% from a year earlier, with a net margin of 69.6%.

Short interest was 2.4M shares at the Oct 15 settlement, down 3.0% from the prior report (1.1% of float, 2.5 days to cover).

Market cap$243.1M394.7M shares
Revenue · quarter$19.4M−0.9% YoY
Diluted EPS$0.03—
P/E · TTM1.8×P/S 2.9×
Net margin69.6%Gross 55.9%
Dividend yieldNone
52-week range0.60 – 1.68−63.3% from high
Volume1.0M1.16× 20-day avg
Volatility · 60d45.6%Annualised
Short % of float1.1%2.5 days to cover
Net cash$460.8MCash $461.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.2%1M −14.7%3M −23.0%6M −36.4%YTD −51.9%1Y −50.3%3Y −68.1%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum36
Revenue growth40
Net margin96
Value (low P/E)97
Size51

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.4M−3.0% vs prior
Days to cover2.5Settled Oct 15
% of float1.1%
Short vol. 10d28.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LABStandard BioTools$0.6160+0.85%−36.4%−0.9%69.6%1.8$243.1M
IMRXImmuneering$3.76+2.17%−27.6%———$243.5MCompare
LFCRLifecore Biomedical$6.44+0.31%+29.8%—−20.9%—$244.1MCompare
KRROKorro Bio$16.62+4.79%+24.6%−100.0%——$244.7MCompare
ABEOAbeona Therapeutics$4.22−0.71%−29.8%+2745.0%−177.4%—$241.3MCompare
GLSIGreenwich LifeSciences$16.35+2.70%−29.1%———$240.0MCompare
CAMPCAMP4 Therapeutics$3.74−2.35%−7.9%+18.8%−1884.8%—$234.7MCompare
VNDAVanda Pharmaceuticals$3.88+3.47%−47.8%+24.1%−32.3%—$234.6MCompare
SIGASIGA Technologies$3.15+1.29%−33.0%−49.5%30.4%—$226.3MCompare

News about Standard BioTools

All news →
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—IRDM, VRME, VAL and LABGlobeNewswire Inc. · Sep 9, 2026▼ NegativeBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)GlobeNewswire Inc. · Jun 19, 2026▼ NegativeStandard BioTools and Treeline Biosciences Announce Merger AgreementBenzinga · Jun 8, 2026▲ PositiveStandard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026GlobeNewswire Inc. · Apr 21, 2026NeutralStandard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026GlobeNewswire Inc. · Feb 10, 2026▲ Positive

Quick answers

What does Standard BioTools do?
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively.
What is LAB's market cap?
$243.14M, based on the Nov 4 close of $0.62.
What is LAB's P/E ratio?
1.8× trailing-twelve-month earnings of $133.08M.
Does Standard BioTools pay a dividend?
No regular cash dividend has been paid in the last year.
How much of LAB is sold short?
2.4M shares, 1.1% of float, as of Oct 15, 2026.
What sector is LAB in?
Healthcare, in the Pharmaceuticals industry.

About Standard BioTools

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

HQ: Boston, MA389 employeesListed Feb 10, 2011standardbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology